Key Highlights: Implications: By pricing its once‑weekly semaglutide at around ₹450 per week via a pre‑filled disposable pen, Alkem is positioning one of the lowest‑cost GLP‑1 op...
Key Highlights: Implications: By launching semaglutide under two differentiated brands with full dose coverage and price points 60%+ below innovator levels, Sun is set to rapidly expand ac...
Key Highlights: Implications: With Sundae vials starting at ₹1,290 per month and a pen device to follow, Eris is leveraging Natco’s low‑cost manufacturing while using its strong diab...
Key Highlights: Implications: By launching Day‑1 multi‑dose vials at ₹1,290–₹1,750 per month and claiming 70–90% discounts vs pens and innovator brands, Natco is setting the floor on...
Key Highlights: Implications: The partnership lets Zydus scale its semaglutide franchise while tapping Torrent’s strong chronic-care reach, accelerating GLP‑1 penetration without stretchin...
Key Highlights: Implications: The deal lets Lupin plug directly into India’s fast‑building GLP‑1 market without its own development risk, while helping Zydus rapidly widen semaglutid...
Key Highlights: Implications: Lilly’s pricing gamble carves a high-end niche, outpacing semaglutide generics from local players through clinical edge and brand power. This sets up fi...
Key Highlights: Implications: Extensior catapults Abbott into the GLP-1 frenzy, grabbing prime shelf space before generics from Eris/Natco crash prices by half—think explosive Tier-2 growt...
Key Highlights: Implications: MSN joins the generics stampede, slashing premium GLP-1 prices and handing endocrinologists budget-friendly options for mass diabetes management.&n...
Key Highlights: Implications: Zydus’ smart-pen assault smashes generic pricing barriers, handing endocrinologists flexible dosing that trumps competitor pens while exploding Tier-2 a...
